In an exciting development for India's growing derma-cosmetic sector, Amwill Healthcare Limited is stepping into the public market with a ₹59.98 crore IPO. This skin-care innovator's offering comprises a fresh issue of 44.04 lakh shares worth ₹48.88 crores, complemented by an offer for sale of 10 lakh shares totaling ₹11.10 crores. The subscription window opens its doors on February 5, 2025, marking a significant milestone in the company's journey to its BSE SME platform listing.
With an attractive price band of ₹105-111 per share (face value ₹10), the offering creates an accessible entry point for investors interested in India's burgeoning skincare market. Retail investors can join with a minimum investment of ₹133,200 for one lot of 1,200 shares, while HNIs can participate with a two-lot minimum of ₹266,400. As the February 7 subscription deadline approaches, discerning investors might want to take a closer look at this emerging player in the specialized derma-cosmetic space before its February 12 market debut.
Amwill Healthcare Limited IPO is a fundraise worth ₹59.98 crores consisting of a fresh issue and an offer for sale with 271,200 shares reserved for the market maker Globalworth Securities Limited. Qualified Institutional Buyers are being offered not more than 20% of the net issue, retail investors are being offered not less than 40% of the net issue and Non-Institutional Investors (NIIs) / High Net-worth Individuals (HNIs) are being offered not less than 40% of the net issue. The IPO will be available for subscription from February 5, 2025, to February 7, 2025, providing an opportunity for investors looking to gain a stake in the derma-cosmetics space.
Amwill Healthcare IPO date | February 5, 2025 - February 7, 2025 |
Price band / Fixed price | ₹105 to ₹111 per share |
Face value | ₹10 per share |
Lot size | 1,200 shares |
Issue type | Book Built Issue IPO |
Fresh issue size | 44,03,600 shares amounting to ₹48.88 crores |
Offer for Sale (OFS) | 10,00,000 shares amounting to ₹11.10 crores |
Total issue size | 54,03,600 shares amounting to ₹59.98 crores |
Listing at | BSE SME |
Market maker portion | 271,200 - Globalworth Securities Ltd |
Shareholding post-issue | 2,00,03,600 shares |
Shareholding pre-issue | 1,56,00,000 shares |
The Amwill Healthcare Limited IPO opens for subscription on February 5, 2025, and closes on February 7, 2025, with allotment scheduled for February 10, 2025.
IPO open date | February 5, 2025 (Wednesday) |
IPO close date | February 7, 2025 (Friday) |
Basis of allotment | February 10, 2025 (Monday) |
Initiation of refunds | February 11, 2025 (Tuesday) |
Credit of shares to Demat account | February 11, 2025 (Tuesday) |
Listing date on BSE / NSE SME | February 12, 2025 (Wednesday) |
Cut-off time for UPI mandate confirmation | 5 PM on February 7, 2025 (Friday) |
Amwill Health Care Limited, established in 2017, has emerged as a specialized derma-cosmetic development company that leverages strategic partnerships with contract manufacturers, distributors, and third-party product development agencies to enhance its operational capabilities. With 84 employees as of September 2024, the company has built a comprehensive portfolio focused on both generic dermatological solutions and targeted treatments for specific skin conditions, ranging from acne and fungal infections to anti-aging and vitiligo care.
The company has adopted a focused market penetration strategy, currently concentrating its efforts in the southern states of Karnataka, Andhra Pradesh, and Telangana. This strategic approach allows Amwill to establish a strong regional presence and build a loyal customer base before expanding into new territories, demonstrating a methodical approach to market growth while maintaining product quality and service excellence.
The company plans to use the net proceeds for funding working capital requirements, marketing and brand-building activities, and general corporate purposes.
The Amwill Healthcare Limited IPO’s key performance indicators, as on March 31, 2024, reflect the company's financial health with a Return on Equity of 73.06%, Return on Capital Employed (ROCE) at 94.16% and the Return on Net-Worth (RoNW) stands at 73.06%. The PAT Margin was 28.53% and the Price to Book Value was 10.09. The company’s market capitalisation is ₹222.04 crore.
Period Ended | September 30, 2024 | March 31, 2024 | March 31, 2023 | March 31, 2022 |
Assets | 28.89 | 18.98 | 12.39 | 6.59 |
Revenue | 23.25 | 44.28 | 30.28 | 27.62 |
Profit After Tax | 6.52 | 12.54 | 3.11 | 2.57 |
Net Worth | 23.68 | 17.16 | 4.6 | 1.49 |
Reserves & Surplus | 8.08 | 17.11 | 4.57 | 1.46 |
Amount in ₹ crores
The pre-IPO EPS is at ₹8.04 while the post-IPO EPS will be ₹6.52. Similarly, the pre-IPO Price to Earnings ratio is 13.81 and will become 17.04 post-IPO.
Amwill Healthcare benefits from a comprehensive product portfolio supported by strong product formulation capabilities, enhancing its ability to innovate within the growing skincare market. The company’s dynamic advisory board of dermatologists further strengthens its product development, allowing for the creation of high-quality dermacosmetic solutions. Additionally, the company operates with an asset-light business model, focusing resources on product development and leveraging third-party manufacturers for production, which helps reduce operational overheads. Amwill Healthcare has built long-standing brand equity through its promoters, enhancing its reputation and establishing strong market trust in its offerings.
The company also boasts an experienced management team with a proven track record in project management and successful implementation of strategies. Its operations in key southern states, such as Karnataka, Andhra Pradesh, and Telangana, provide a solid market base and an opportunity for expansion. Moreover, the company’s deep relationships with dermatologists play a crucial role in ensuring product acceptance and effectiveness, contributing to its competitive advantage in the derma-cosmetic space. These strengths position Ken Enterprises well for future growth and market penetration.
Amwill Healthcare faces several risks due to its reliance on third-party contract manufacturers. This dependency exposes the company to potential disruptions in the supply chain, quality control issues, and delays in production, which could affect overall profitability. Additionally, a significant portion of its revenue is derived from a limited number of products. If demand for these products declines or the company fails to innovate effectively, its financial stability could be impacted. The company's focus on a narrow product range raises concerns about its ability to diversify and mitigate risks from changing market conditions.
Furthermore, the company's operations are concentrated in specific geographic regions (Karnataka, Andhra Pradesh, and Telangana). This geographic concentration makes the business vulnerable to regional economic downturns or local disruptions. Additionally, the company is heavily reliant on Amderma Healthcare LLP for distribution and storage, and any performance issues or breaches in their agreement could significantly disrupt operations. Furthermore, potential conflicts of interest between its promoters and other entities involved in similar industry segments may create internal competition, which could hinder growth and profitability.
Investing early in Amwill Healthcare Limited offers the chance to be part of the company’s growth in the derma-cosmetics sector. However, investors should evaluate key factors such as the company’s operational history, financial stability, industry trends, and growth plans, while aligning this opportunity with their personal investment goals and risk tolerance. It’s advisable to thoroughly review the offer document and seek professional guidance, if necessary, to make a well-informed decision about participating in the IPO.
What is the Amwill Healthcare Limited IPO?
The Amwill Healthcare Limited IPO is an BSE SME offering consisting of a fresh issue of 44.04 lakh equity shares and an offer for sale of 10 lakh equity shares with a face value of ₹10 per share, aiming to raise a total of ₹59.98 crores. The price band has been set between ₹105 to ₹111 per share, with a minimum order quantity of 1,200 shares. This IPO will be open for subscription from February 5, 2025, to February 7, 2025. Unistone Capital Private Limited is the book-running lead manager, Bigshare Services Private Limited is the registrar while Globalworth Securities Limited is the market maker.
When will the Amwill Healthcare IPO open?
The Amwill Healthcare Limited IPO will open for subscription on February 5, 2025, and will close on February 7, 2025.
When is the Amwill Healthcare IPO listing date?
The tentative listing date for the Amwill Healthcare Limited IPO is Wednesday, February 12, 2025.